Abbott announces first step toward its software-guided balloon-expandable tavi system to treat aortic stenosis

The investigational transcatheter aortic valve implantation (tavi) system will complement abbott's navitor™ tavi system for aortic stenosis, a common and life-threatening heart valve disease the investigational system is designed to offer best-in-class heart blood flow, ease of use and precision approximately 9% of older americans have aortic stenosis1 abbott park, ill., nov. 25, 2024 /prnewswire/ -- abbott (nyse: abt) today announced the first patient procedures with its investigational transcatheter aortic valve implantation (tavi) balloon-expandable system for treating symptomatic severe aortic stenosis.
ABT Ratings Summary
ABT Quant Ranking